Tumor-Specific Differences, Genomic Alterations of Biliary Tract Cancers Identified
Gastrointestinal cancers have a diverse landscape of clinically relevant genomic alterations (CRGA) that could lead to targeted drug therapy.
Gastrointestinal cancers have a diverse landscape of clinically relevant genomic alterations (CRGA) that could lead to targeted drug therapy.
Endothelial nitric oxide synthase (eNOS) VNTR and eNOS -786 could determine outcomes in advanced hepatocellular carcinoma treated with sorafenib,
Baseline α-fetoprotein (AFP) levels may be a predictive marker for advanced hepatocellular carcinoma receiving ramucirumab.
Comprehensive genomic profiling (CGP) shows promise in advanced esophageal squamous cell carcinomas (ESCC) and adenocarcinoma (EAC).
Hybrid minimally invasive oesophagectomy (HMIO) is associated with fewer complications for resectable oesphageal cancer.
Laproscopically assisted distal gastrectomy (LADG) is safe for patients with clinical stage 1 gastric cancer.
Pembrolizumab demonstrated promising antitumor activity and manageable toxicity in advanced gastric cancer.
Addition of onartuzumab to mFOLFOX6 for gastroesophageal adenocarcinoma (GEC) did not improve survival.
AMG-337 caused responses in patients with MET-amplified gastroesophageal junction, gastric cancer, and esophageal cancer.